Position in RLYB
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,371,521
-$1,123,024 QoQ
Shares Held
152,901
-66.4% QoQ
Ownership
2.88%
of shares outstanding
% of Portfolio
0.21%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in RLYB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JOHNSON & JOHNSON holds $757,781,542 across 11 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTGX |
Protagonist Therapeutics, Inc
|
2,449,183 | $300,220,852 | |
| 2 | NBTX |
Nanobiotix S.A.
|
5,623,816 | $212,017,863 | |
| 3 | MGTX |
MeiraGTx Holdings plc
|
6,641,064 | $89,720,774 | |
| 4 | RAPP |
Rapport Therapeutics, Inc.
|
1,784,517 | $74,360,823 | |
| 5 | CTNM |
Contineum Therapeutics, Inc.
|
1,979,173 | $32,438,645 | |
| 6 | LEGN |
Legend Biotech Corp
|
814,586 | $23,525,243 | |
| 7 | XNCR |
Xencor Inc
|
748,062 | $12,043,798 | |
| 8 | FATE |
Fate Therapeutics Inc
|
3,379,064 | $9,123,472 |
All Filings in RLYB
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,371,521 | 152,901 | Shares | Sole | 2026-04-13 | |
| 2026-03-31 | $1,371,521 | 152,901 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $2,494,545 | 3,636,363 | Shares | Defined | 2026-03-18 | |
| 2025-09-30 | $1,814,545 | 3,636,363 | Shares | Defined | 2026-03-18 | |
| 2025-06-30 | $1,229,090 | 3,636,363 | Shares | Defined | 2025-07-22 | |
| 2025-03-31 | $2,381,817 | 3,636,363 | Shares | Defined | 2025-05-07 | |
| 2024-12-31 | $3,490,908 | 3,636,363 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $4,254,544 | 3,636,363 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $4,872,726 | 3,636,363 | Shares | Defined | 2024-08-09 | |
| No filing history on record for this holder in this stock. | ||||||